308 related articles for article (PubMed ID: 23663685)
1. Seven clinical conundrums in the treatment of ANCA-associated vasculitis.
Alba MA; Flores-Suárez LF
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S74-83. PubMed ID: 23663685
[TBL] [Abstract][Full Text] [Related]
2. [Uptodate in the management and treatment of ANCA-associated vasculitis].
Belaconi IN; Toma CL; Bogdan MA
Pneumologia; 2014; 63(2):78-80, 83-6. PubMed ID: 25241554
[TBL] [Abstract][Full Text] [Related]
3. L44. Management of relapses in vasculitis.
Mouthon L
Presse Med; 2013 Apr; 42(4 Pt 2):619-22. PubMed ID: 23477710
[No Abstract] [Full Text] [Related]
4. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?
Hoffman GS
Presse Med; 2013 Apr; 42(4 Pt 2):643-50. PubMed ID: 23474045
[No Abstract] [Full Text] [Related]
5. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
6. Use of methotrexate in ANCA-associated vasculitides.
Reinhold-Keller E; de Groot K
Clin Exp Rheumatol; 2010; 28(5 Suppl 61):S178-82. PubMed ID: 21044456
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and management of small vessel vasculitides].
Pettersson T; Karjalainen A
Duodecim; 2010; 126(12):1496-507. PubMed ID: 20617753
[TBL] [Abstract][Full Text] [Related]
8. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
Zand L; Specks U; Sethi S; Fervenza FC
Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
[TBL] [Abstract][Full Text] [Related]
9. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
10. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
[TBL] [Abstract][Full Text] [Related]
11. Treating vasculitis with conventional immunosuppressive agents.
Jayne D
Cleve Clin J Med; 2012 Nov; 79 Suppl 3():S46-9. PubMed ID: 23203646
[TBL] [Abstract][Full Text] [Related]
12. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
Rich EN; Brown KK
Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
[TBL] [Abstract][Full Text] [Related]
13. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.
Lally L; Spiera R
Rheum Dis Clin North Am; 2015; 41(1):1-19, vii. PubMed ID: 25399936
[TBL] [Abstract][Full Text] [Related]
14. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh D; Walsh M; Westman K; Jayne DR;
N Engl J Med; 2010 Jul; 363(3):211-20. PubMed ID: 20647198
[TBL] [Abstract][Full Text] [Related]
15. Management of ANCA associated vasculitis.
Wallace ZS; Miloslavsky EM
BMJ; 2020 Mar; 368():m421. PubMed ID: 32188597
[TBL] [Abstract][Full Text] [Related]
16. Treatment Strategies in ANCA-Associated Vasculitis.
Emejuaiwe N
Curr Rheumatol Rep; 2019 May; 21(7):33. PubMed ID: 31123922
[TBL] [Abstract][Full Text] [Related]
17. Changing landscape of immunosuppression in ANCA-associated vasculitis.
Moiseev SV; Smitienko I; Bulanov N; Karovaikina E; Novikov PI
Ann Rheum Dis; 2020 May; 79(5):e59. PubMed ID: 30755415
[No Abstract] [Full Text] [Related]
18. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
[TBL] [Abstract][Full Text] [Related]
19. [De-escalation of therapy in ANCA-associated vasculitides].
Schinke S; Riemekasten G; Lamprecht P
Z Rheumatol; 2017 Feb; 76(1):15-20. PubMed ID: 27933390
[TBL] [Abstract][Full Text] [Related]
20. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies.
Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Fujimoto S; Dobashi H; Yuzawa Y; Yamagata K; Muso E; Arimura Y; Makino H
Mod Rheumatol; 2021 Jan; 31(1):205-213. PubMed ID: 31859544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
